-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
So far, seven batches and eight rounds
So far, seven batches and eight rounds
The average decline seems to be peaceful, but the large variety of cliff-like declines, cruel is still the same, and will always be cruel
The average decline seems to be peaceful, but the large variety of cliff-like declines, cruel is still the same, and will always be cruel
It's time to let go of fantasies
It's time to let go of fantasies
Because the collection of generic drugs as the main body is essentially a game of the stock market, the pattern of excessive homogenization competition will never change
Because the collection of generic drugs as the main body is essentially a game of the stock market, the pattern of excessive homogenization competition will never change
Although the lowest winning price does not directly correspond to the largest market share, the low price can give priority to supplying developed regions, which is still low-price oriented
Although the lowest winning price does not directly correspond to the largest market share, the low price can give priority to supplying developed regions, which is still low-price oriented
An inner-volume market, encountering the prisoner's dilemma, the original price system naturally collapsed
An inner-volume market, encountering the prisoner's dilemma, the original price system naturally collapsed
Since then, generic drugs have no comfort zone, and the choice of pharmaceutical companies is to stay in the shuluo field or to go to innovative drugs?
Since then, generic drugs have no comfort zone, and the choice of pharmaceutical companies is to stay in the shuluo field or to go to innovative drugs?Because the epidemic was postponed for half a year, the seventh batch of collection and procurement was unprecedentedly crowded, and 29 products were approved
Collecting no winners, analyzing the results of a pharmaceutical company in the competitive landscape and market share, it is meaningless, and each other is just 50 steps of laughter and 100 steps, the difference between fiasco and fiasco
.
.
There are more than 10 large varieties with a sales scale of more than 1 billion yuan, and today we are witnessing the end
of the two major miracle drugs.
of the two major miracle drugs.
Roll King is an injection of omeprazole, with a total of 28 companies competing
.
According to statistics, in 2020, the sales scale of omeprazole sodium injection in the domestic medical market was 5.
210 billion yuan, ranking first in the sales volume of similar treatment of peptic ulcer drug injection products, of which the highest market share was Aosaicon, reaching 41.
55%, and the original pharmaceutical company AstraZeneca ranked second, at 14.
31%.
Today, Cylon Pharmaceuticals was selected for injection of omeprazole sodium (40mg), quoted at 1.
16 yuan / stick, a decrease of 91.
7%.
.
According to statistics, in 2020, the sales scale of omeprazole sodium injection in the domestic medical market was 5.
210 billion yuan, ranking first in the sales volume of similar treatment of peptic ulcer drug injection products, of which the highest market share was Aosaicon, reaching 41.
55%, and the original pharmaceutical company AstraZeneca ranked second, at 14.
31%.
Today, Cylon Pharmaceuticals was selected for injection of omeprazole sodium (40mg), quoted at 1.
16 yuan / stick, a decrease of 91.
7%.
Another volume of king is the flu miracle drug oseltamivir capsules, a total of 16 companies compete
.
In 2019, in domestic public medical institutions and urban physical pharmacies, oseltamivir totaled sales of 6.
5 billion yuan
.
At one point, East Sunshine Medicine Covir once occupied nearly 90% of the market share in the domestic oseltamivir market, and 2019 was the highest light moment, with sales revenue of 5.
939 billion yuan
.
The prevention and control of the new crown epidemic has also been contained to the influenza virus, and in 2020, kewei sales revenue is 2.
072 billion yuan, and in 2021, sales revenue is 560 million yuan
.
.
In 2019, in domestic public medical institutions and urban physical pharmacies, oseltamivir totaled sales of 6.
5 billion yuan
.
At one point, East Sunshine Medicine Covir once occupied nearly 90% of the market share in the domestic oseltamivir market, and 2019 was the highest light moment, with sales revenue of 5.
939 billion yuan
.
The prevention and control of the new crown epidemic has also been contained to the influenza virus, and in 2020, kewei sales revenue is 2.
072 billion yuan, and in 2021, sales revenue is 560 million yuan
.
Today, the lowest price of oseltamivir is 0.
99 yuan / tablet, and the winning company is East Sunshine Medicine
.
The variety of 30mg specification limit is 6.
45 yuan / piece, 75mg specification limit is 13.
01 yuan / piece
.
According to the announcement of the proposed selection released by Kelun Pharmaceutical, its 75mg specification 10 capsules / box of oseltamivir, the proposed selection price is 14.
96 yuan, a decrease of 88.
5%.
99 yuan / tablet, and the winning company is East Sunshine Medicine
.
The variety of 30mg specification limit is 6.
45 yuan / piece, 75mg specification limit is 13.
01 yuan / piece
.
According to the announcement of the proposed selection released by Kelun Pharmaceutical, its 75mg specification 10 capsules / box of oseltamivir, the proposed selection price is 14.
96 yuan, a decrease of 88.
5%.
Oseltamivir's ups and downs in life, to the end of the life cycle, can be described as lingering
.
In the case of a market size that has shrunk by 70% or 80%, the market share has lost its value
.
.
In the case of a market size that has shrunk by 70% or 80%, the market share has lost its value
.
The end of the old miracle medicine also means that the intergenerational change is underway
.
.
Omeprazole is a proton pump inhibitor (PPI) with many disadvantages, short half-life, insufficient acid suppression, limited time to take, slow onset of action, and obvious
side effects.
The new generation of acid-suppressing drugs P-CAB has made comprehensive progress, in April this year, Luoxin Pharmaceutical 1 class of new drugs tigora raw tablets were approved for listing, becoming the first domestic P-CAB drug, which has the advantage
of comprehensive substitution for existing PPI drugs.
side effects.
The new generation of acid-suppressing drugs P-CAB has made comprehensive progress, in April this year, Luoxin Pharmaceutical 1 class of new drugs tigora raw tablets were approved for listing, becoming the first domestic P-CAB drug, which has the advantage
of comprehensive substitution for existing PPI drugs.
Roche's new anti-flu drug mabaloszavir was approved for market in China last year, which is the first and only single-dose oral drug approved to treat influenza in 20 years, and it only takes one dose of the whole drug to significantly reduce viral detoxification within 24 hours, while oseltamivir usually takes 72 hours to function
.
.
Instead of rolling up in imitation old drugs, it is better to turn to innovative drugs
with a relaxed competitive landscape.
with a relaxed competitive landscape.
There are more than 10 varieties of 6 enterprises included in this batch of collection, including Qilu Pharmaceutical, Yangzijiang Pharmaceutical, Kelun Pharmaceutical, CSPC Pharmaceutical Group, China Biopharmaceuticals, Chengdu Beite, which can be called a severe addict of generic drugs, which is not a glorious thing, Qilu Pharmaceutical is known for its
price butcher.
But it should also be seen that some enterprises are also working hard to transform, Kelun Pharmaceutical force ADC drugs, synthetic biology, CSPC Pharmaceutical Group fully embrace the most cutting-edge field, the new crown mRNA vaccine began phase II clinical, China's biopharmaceuticals in the BD ability to ride the dust, always four or two thousand pounds
.
price butcher.
But it should also be seen that some enterprises are also working hard to transform, Kelun Pharmaceutical force ADC drugs, synthetic biology, CSPC Pharmaceutical Group fully embrace the most cutting-edge field, the new crown mRNA vaccine began phase II clinical, China's biopharmaceuticals in the BD ability to ride the dust, always four or two thousand pounds
.
The cost savings of the state organization's collection and procurement have reached more than 260 billion yuan, where is the money saved?
The cost savings of the state organization's collection and procurement have reached more than 260 billion yuan, where is the money saved?After all, the rise of domestic innovative drugs is the best way
to meet the unmet clinical needs and improve the accessibility of drugs.
to meet the unmet clinical needs and improve the accessibility of drugs.
However, in 2018, 2019, 2020 and 2021, the overall average decline in medical insurance negotiations was 56.
7%, 60.
7%, 53.
8% and 61.
7%, respectively, and the support of the payment environment for the growth of domestic innovative drugs in infancy needs to be strengthened
.
7%, 60.
7%, 53.
8% and 61.
7%, respectively, and the support of the payment environment for the growth of domestic innovative drugs in infancy needs to be strengthened
.